Hansoh Pharmaceutical Group Company Limited

SEHK:3692 주식 보고서

시가총액: HK$108.4b

Hansoh Pharmaceutical Group 미래 성장

Future 기준 확인 1/6

Hansoh Pharmaceutical Group (는) 각각 연간 2.7% 및 6.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 2.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.4% 로 예상됩니다.

주요 정보

2.7%

수익 성장률

2.3%

EPS 성장률

Pharmaceuticals 수익 성장11.1%
매출 성장률6.9%
향후 자기자본 수익률12.4%
애널리스트 커버리지

Good

마지막 업데이트18 Nov 2024

최근 미래 성장 업데이트

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01
Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Nov 21
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Nov 04
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Aug 28
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Aug 07
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Jul 16
If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23
Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01
Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28
Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04
There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Dec 08
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Oct 12
Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

Sep 14
Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 10
Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Jun 11
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jan 23
Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Dec 01
Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Oct 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Aug 28
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Jun 09
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

May 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

Apr 22
Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Feb 06
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

수익 및 매출 성장 예측

SEHK:3692 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202613,8664,4334,3844,22520
12/31/202512,3673,8993,8263,94423
12/31/202412,0564,1493,6793,37223
6/30/202412,0984,7144,1374,653N/A
3/31/202411,1013,9963,4463,885N/A
12/31/202310,1043,2782,7543,116N/A
9/30/20239,7822,9262,2922,615N/A
6/30/20239,4592,5751,8302,114N/A
3/31/20239,4212,5792,1402,427N/A
12/31/20229,3822,5842,4492,741N/A
9/30/20229,6752,6522,6463,004N/A
6/30/20229,9682,7202,8423,267N/A
3/31/20229,9522,7172,4722,922N/A
12/31/20219,9352,7132,1022,577N/A
9/30/20219,5242,6751,4152,345N/A
6/30/20219,1122,6387292,113N/A
3/31/20218,9012,6038402,252N/A
12/31/20208,6902,5699512,390N/A
9/30/20208,3772,5261,7752,802N/A
6/30/20208,0632,4832,6003,213N/A
3/31/20208,3732,5202,6663,271N/A
12/31/20198,6832,5572,7323,330N/A
9/30/20198,6152,3572,5293,092N/A
6/30/20198,5482,1572,3252,854N/A
3/31/20198,1352,0302,0082,463N/A
12/31/20187,7221,9031,6902,072N/A
12/31/20176,1861,595N/A1,402N/A
12/31/20165,4331,476N/A1,247N/A

애널리스트 미래 성장 예측

수입 대 저축률: 3692 의 연간 예상 수익 증가율( 2.7% )이 saving rate( 2.3% 보다 높습니다. ).

수익 vs 시장: 3692 의 연간 수익( 2.7% ) Hong Kong 시장( 11.7% 보다 느리게 성장할 것으로 예상됩니다. 11.7% 연간).

고성장 수익: 3692 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 3692 의 수익(연간 6.9% ) Hong Kong 시장( 7.8% 보다 느리게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 3692 의 수익(연간 6.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: 3692 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 12.4 %).


성장 기업 발견